Showing results (101-110 of 215) with videos related to

Sort By:
Pageof 22
Blood|March 2, 2019
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Jae Hoon Lee, Philippe Moreau, et al.
Expert Review of Hematology|March 10, 2020
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRdAjai Chari, Paul G Richardson, Dorothy Romanus, et al.
Clinical Lymphoma & Myeloma|December 10, 2008
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairmentJoan Bladé, Pieter Sonneveld, Jesús F San Miguel, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcomeJoan Bladé, Pieter Sonneveld, Jesús F San Miguel, et al.
Blood Cancer Journal|November 11, 2018
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world settingPaul G Richardson, Jesus F San Miguel, Philippe Moreau, et al.
British Journal of Haematology|September 9, 2021
Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemiaRenata Bezdekova, Tomas Jelinek, Romana Kralova, et al.
European Journal of Haematology|November 26, 2019
Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patientsDavid Vrabel, Lenka Sedlarikova, Lenka Besse, et al.
Biomedicines|October 27, 2022
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with PlasmacytomasMartin Stork, Sabina Sevcikova, Tomas Jelinek, et al.
Clinical Hematology International|October 1, 2021
Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?Anna Suska, David H Vesole, Jorge J Castillo, et al.
Blood Advances|July 12, 2018
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trialsAjai Chari, A Keith Stewart, Stuart D Russell, et al.
Pageof 22